Project Grant R44DK142200
Award Date
8/1/25
Completion Date
7/31/27
Dollars Obligated
$1M
Awardee
Emmyon, Inc. (M8CMYGLPB5H7)
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Minnesota, USA
Similar Awards
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded Biotherapeutics, Inc. a $359,625 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports the development of next-generation, once-daily oral therapeutic candidates for the treatment of pre-diabetes and type 2 diabetes. Key research objectives include evaluating the therapeutic efficacy of the lead drug candidate on lipid metabolism, insulin...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) aims to evaluate the therapeutic potential of a new orally active small molecule in obesity-linked diabetic models. The $418,560 award, effective September 1, 2024 through April 30, 2025, supports research to: 1) analyze the pharmacokinetic profiles of a new small molecule, 2) investigate the efficacy and...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $659,199 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to the University of Pittsburgh. The grant, awarded on February 25, 2025, supports research to investigate a novel pathway by which hepatocyte-derived growth differentiation factor 15 (GDF15) can improve obesity-associated insulin resistance independent of changes in body weight and the GDF15...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $582,825 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Epic Nutrition For Y LLC in Troy, Michigan. The grant supports research to develop a novel probiotic, Clostridium cochlearium 2316 (CC), as a safe, low-cost, and long-term dietary supplement/medical food for managing obesity and insulin resistance. The 2-year project aims to assess the...
This federal Project Grant award of $706,199 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to uncover the mechanisms of NAD depletion in obesity-induced pancreatic beta cell dysfunction and test strategies to restore beta cell mass and function in type 2 diabetes models. The award aims to define changes in NAD biosynthesis and degradation pathways...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $1,561,974 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Syntis Bio Inc. in Dorchester, MA. The goal of this Fast-Track SBIR project is to develop an oral pill that blocks nutrient absorption in the duodenum, mimicking the effects of gastric bypass surgery for obesity treatment. Syntis Bio will optimize their Gastrointestinal Synthetic...
This federal Project Grant award of $1,600,000 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research at Beth Israel Deaconess Medical Center, Inc. (BIDMC) to develop a computational pharmacology approach for coordinating the regulation of multiple neuron types related to energy balance and satiety. The research aims to identify combinations of 2-10 ligands...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), is dedicated to the development and optimization of non-peptide ligands designed to activate insulin receptors. The $772,383 research project aims to transform approaches to glycemic control in the management of diabetes by uncovering a new generation of receptor modulators that could...
This federal Project Grant award of $444,867.00 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the role of the UPR transducer XBP1 in pancreatic beta cell survival and function under metabolic stress. The research will use a novel mouse model to elucidate the pathological role of XBP1s in beta cell integrity under metabolic stress, in order to...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $306,872.00 to Geminii Inc. to develop a "NeuWave" digital therapeutic platform that uses electromagnetic fields to treat Type 2 Diabetes. The goal is to demonstrate the feasibility and safety of this non-invasive, at-home approach to passively manage Type 2 Diabetes by rewiring...